Roche Holding Ltd. (RHHBY) reports healthcare developments across medicines, diagnostics and digital health, including updates from Genentech as a member of the Roche Group. Recurring news covers operating and financial results, regional sales trends, product performance and regulatory disclosures tied to the company’s pharmaceutical and diagnostic portfolios.
Company updates frequently feature ophthalmology products and pipeline assets such as Vabysmo, Susvimo and vamikibart across retinal conditions including diabetic macular edema and neovascular age-related macular degeneration. Roche also reports clinical data in neurology and autoimmune disease, including fenebrutinib in multiple sclerosis and ENSPRYNG in myelin oligodendrocyte glycoprotein antibody-associated disease, along with diagnostics approvals and patient-education initiatives.
Roche (OTCQX:RHHBY) has received CE mark approval for Contivue, its Port Delivery Platform containing Susvimo, for treating neovascular age-related macular degeneration (nAMD). The platform consists of an eye implant and four ancillary devices for implant management.
New seven-year data from the LADDER study demonstrates strong efficacy, with patients maintaining stable vision and retinal anatomy. The study showed only a six-letter decline in best-corrected visual acuity over seven years, with 95% durability maintained in patients.
The treatment requires only two refills per year, offering a significant improvement over current monthly intravitreal injections. Susvimo is currently under EMA review and could become the first continuous delivery treatment for nAMD, which affects 1.7 million people in the European Union.
Roche (OTCQX:RHHBY) and Alnylam have announced plans to advance zilebesiran into a Phase III cardiovascular outcomes trial (CVOT) for uncontrolled hypertension treatment. The decision follows comprehensive Phase II KARDIA program results, particularly KARDIA-3, which demonstrated clinically meaningful blood pressure reductions.
The KARDIA-3 study showed that zilebesiran (300mg) achieved placebo-adjusted systolic blood pressure reductions of -5.0 mmHg at month three and -3.9 mmHg at month six. Notably, patients on diuretics with baseline BP >140 mmHg showed stronger results of -9.2 mmHg and -8.3 mmHg at three and six months, respectively.
The upcoming ZENITH Phase III trial will enroll approximately 11,000 patients, evaluating zilebesiran's effectiveness in reducing cardiovascular events in high-risk patients on multiple antihypertensives.
Genentech (OTCQX:RHHBY) and Alnylam announced plans to advance zilebesiran into a Phase III cardiovascular outcomes trial (CVOT) for uncontrolled hypertension treatment. The decision follows positive results from the comprehensive KARDIA Phase II program, particularly KARDIA-3 study results presented at ESC Congress 2025.
The KARDIA-3 study demonstrated that zilebesiran (300mg) achieved clinically meaningful blood pressure reductions at month three (-5.0 mmHg; p=0.0431) with sustained benefits through month six. Notably, patients on diuretics with baseline BP >140 mmHg showed significant improvements (-9.2 mmHg at month three).
The upcoming global ZENITH Phase III trial will enroll approximately 11,000 patients, evaluating zilebesiran (300mg) versus placebo in patients with uncontrolled hypertension on multiple antihypertensives. The twice-yearly dosing schedule aims to address poor adherence issues affecting up to 80% of hypertension patients worldwide.
Genentech, a Roche Group company (OTCQX: RHHBY), has broken ground on a $700 million manufacturing facility in Holly Springs, North Carolina. The 700,000-square-foot facility represents Genentech's first East Coast manufacturing site and is part of a larger $50 billion investment in U.S. manufacturing, infrastructure, and R&D.
The state-of-the-art facility will focus on producing next-generation metabolic medicines, including obesity treatments. Set to be operational by 2029, the project will create over 400 permanent manufacturing jobs and 1,500 construction jobs. The 100-acre site includes space for future expansion and will feature modern biomanufacturing technologies, advanced automation, and digital capabilities.
Roche's (OTCQX:RHHBY) subsidiary Genentech has initiated construction of a $700 million manufacturing facility in Holly Springs, North Carolina. The 65,000 m² facility, set to be operational by 2029, represents Genentech's first East Coast manufacturing site and is part of Roche's larger $50 billion investment in US operations.
The strategic facility will focus on producing next-generation metabolic medicines, including obesity treatments, and is expected to create more than 1,900 jobs. Located on a 400,000 m² lot with expansion potential, the site was chosen for its skilled workforce, academic institutions, and proximity to other life science companies.
Roche (OTCQX: RHHBY) has announced compelling 5-year data for Susvimo in treating neovascular age-related macular degeneration (nAMD). The Phase III Portal study demonstrated that Susvimo maintained vision with just two refills per year, showing approximately 95% durability in patients requiring no supplemental treatment between refills.
The study tracked 352 patients over five years, with the Susvimo cohort maintaining vision scores from 74.4 letters at baseline to 67.6 letters at 5 years. The IVT-Susvimo cohort showed similar results, from 76.3 to 68.6 letters. Notably, half of all patients maintained better than 20/40 vision at the five-year mark, with stable central subfield thickness measurements.
Susvimo's Port Delivery Platform represents a significant advancement over current treatments that may require monthly eye injections, offering a one-time surgical implant that delivers continuous medication.
Genentech (OTCQX: RHHBY) announced compelling five-year data for Susvimo in treating wet age-related macular degeneration (AMD). The Phase III Portal study demonstrated that Susvimo maintained vision with just two refills per year in approximately 95% of patients, requiring no supplemental treatment between refills.
The study showed consistent disease control, with patients maintaining better than 20/40 vision at five years. Best-corrected visual acuity (BCVA) scores were 67.6 letters at 5 years in the Susvimo cohort and 68.6 letters in the IVT-Susvimo cohort. Central subfield thickness remained stable with minimal changes from baseline.
Susvimo utilizes a unique Port Delivery Platform, involving a refillable eye implant that delivers ranibizumab continuously, offering an alternative to monthly eye injections for wet AMD patients.
Genentech and Roche (OTCQX: RHHBY) presented significant advancements in Alzheimer's disease research at AAIC 2025. The Phase Ib/IIa Brainshuttle™ AD study of trontinemab showed 91% of participants becoming amyloid PET negative, with ARIA-E remaining below 5%. The company announced plans for Phase III TRONTIER 1 and 2 trials in early symptomatic Alzheimer's disease, starting in 2025.
Additionally, Roche revealed plans for a new Phase III trial investigating trontinemab in preclinical Alzheimer's disease. The company's Elecsys® pTau217 blood test demonstrated comparable results to PET scans for amyloid pathology detection, potentially transforming Alzheimer's diagnosis with a simple blood draw versus traditional methods.
Roche (OTCQX:RHHBY) presented significant advances in Alzheimer's disease research at AAIC 2025. Their investigational drug trontinemab showed promising Phase Ib/IIa results with 91% of participants becoming amyloid PET negative and ARIA-E rates remaining below 5%. The company announced plans for two Phase III trials (TRONTIER 1 and 2) in early symptomatic Alzheimer's, plus a new Phase III trial for preclinical Alzheimer's.
Additionally, Roche's Elecsys pTau217 blood test, which received FDA Breakthrough Device Designation, demonstrated comparable accuracy to PET scans in detecting amyloid pathology. This diagnostic advancement could significantly improve early detection and treatment access, addressing the critical issue where 75% of Alzheimer's cases globally remain undiagnosed.
Roche (OTCQX:RHHBY) announced that the European Medicines Agency's CHMP has issued a negative opinion on the conditional marketing authorization for Elevidys™ (delandistrogene moxeparvovec) in the EU. The therapy was intended for ambulatory individuals aged 3-7 years with Duchenne muscular dystrophy (DMD).
Despite the Phase III EMBARK study showing sustained disease stabilization and clinically meaningful improvements across secondary endpoints, the primary endpoint was not met after one year. The therapy has treated over 900 individuals with DMD, including 760 ambulatory patients, in clinical and real-world settings. Roche plans to continue dialogue with EMA to explore potential paths forward.